Drug intelligence / Profile preview

NOVOCART Inject plus

Development stage: Phase 3
Lead developer: Tetec
Modality: Cell Therapies
Administration: Implantation

Overview

NOVOCART Inject plus is a third-generation autologous chondrocyte implantation (ACI) cell therapy product developed by Tetec AG (now part of Octane Medical Group). It is an injectable mixture comprising a patient's own cultured cartilage cells (autologous chondrocytes) suspended in a PEG-albumin-hyaluronic acid hydrogel. The therapy is designed to treat cartilage defects, primarily in the knee, by regenerating damaged articular cartilage and restoring joint function. The treatment involves harvesting a cartilage biopsy from the patient, culturing the chondrocytes, and then implanting the cell-hydrogel mixture into the defect site.

Brand names: NOVOCART Inject plus
Other names: NOVOCARTNOVOCART Inject

Beyond the preview

Go deeper on NOVOCART Inject plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOVOCART Inject plus.

Explore the full profile